HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein

Pharmaceutical Research

Volumn 18, Issue 6, 2001, Pages 800-806

  Wang, E J ^a   Casciano, C N ^a   Clement, R P ^a   Johnson, W W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HMG CoA; Inhibitor; MDR; P glycoprotein; Statins

Indexed keywords

ADENOSINE TRIPHOSPHATE; ATORVASTATIN; CYTOCHROME P450 3A4; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

AEROBIC METABOLISM; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG TOLERANCE; HYPERCHOLESTEROLEMIA; IC 50; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTICHOLESTEREMIC AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MICE; P-GLYCOPROTEIN; PRAVASTATIN; PYRROLES; SIMVASTATIN;

EID: 0034866642     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011036428972     Document Type: Article

References (39)

1. Multiple-drug resistance in human cancer
2. Biochemistry of multidrug resistance mediated by the multidrug transporter
3. The mouse multidrug resistance gene family: Structural and functional analysis
4. P-glycoprotein-a mediator of multidrug resistance in tumour cells
5. P-glycoprotein and multidrug resistance
6. Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein
7. Two transport binding sites of P-glycoprotein are unequal yet contingent: Initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependency
8. Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: Evidence for half-of-the-sites reactivity
9. Regulation of cholesterol metabolism
10. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia
11. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar
12. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
13. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors
14. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
15. Accumulation of lovastatin, but not pravastatin, in the blood of cylcosporine-treated kidney graft patients after multiple doses
16. Simvastatin, but not pravastatin, is very susceptible to interact with the CYP3A inhibitor itraconazole
17. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients
18. Rhabdomyolysis in patients treated with simvastatin and cyclosporin: Role of hepatic cytochrome P450 system activity
19. Massive rhabdomyolysis and simvastatin
20. Tissue-selective uptake of pravastatin in rats: Contribution of a specific carrier-mediated uptake system
21. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: Erythromycin and ethinyl estradiol
22. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
23. HMG-CoA reductase mediates the biologic effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein expressing cells
24. Atorvastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter
25. Biliary excretion of pravastatin in rats: Contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT)
26. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats
27. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein
28. Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis
29. Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein
30. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal
31. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein
32. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
33. A general pattern for substrate recognition by P-glycoprotein
34. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
35. Effects of pravastatin on outcomes after cardiac transplantation
36. Erythromycin coadministration increases plasma atorvastatin concentrations
37. Human multidrug-resistant (MRP,p190) myeloid leukemia HL-60cells in vitro: Resistance to the mevalonate pathway inhibitor lovastatin
38. The role of passive transbilayer drug movement in multidrug resistance and its modulation
39. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane